galectin-7 CRISPR/Cas9 KO Plasmid (m): sc-421419
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- galectin-7 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the galectin-7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: galectin-7 Antibody (A-8): sc-271473
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
galectin-7 CRISPR/Cas9 KO Plasmid (m) | sc-421419 | 20 µg | $397.00 |
Overview
Mouse Lgals7 encodes galectin-7, a β-galactoside–binding lectin enriched in stratified epithelia that regulates cell–cell and cell–matrix interactions through glycan recognition. Galectin-7 has been linked to control of keratinocyte proliferation and differentiation, epithelial barrier homeostasis, and stress responses, with reported roles in modulating apoptosis and inflammatory signaling. Through its effects on adhesion and wound repair programs, Lgals7 is relevant to studies of skin biology, epithelial remodeling, and tumor-associated phenotypes such as migration and invasion. Dysregulated galectin-7 expression has been associated with inflammatory skin disorders and epithelial cancers, supporting its use as a mechanistic node in pathway and biomarker-focused research.
galectin-7 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Lgals7 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Lgals7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Lgals7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish galectin-7 protein expression.
This CRISPR knockout system enables efficient generation of Lgals7-deficient cell models for investigation of galectin-7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Lgals7 exon(s) critical for galectin-7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Lgals7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by galectin-7 CRISPR/Cas9 KO Plasmid (m) and galectin-7 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Lgals7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by galectin-7 HDR Plasmid (m) and galectin-7 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Lgals7 homology arms to support homology-directed repair at defined Lgals7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.